Previous studies suggest CerS2-derived C22:0 and C24:0 ceramides may not be deleterious in liver, as knockdown of CerS2 led to glucose intolerance, impaired insulin signaling in the liver and the development of hepatic tumors in mice (18, 62). The gene discussed is CERS2; the disease is Glucose intolerance.